The Europe gastrointestinal drugs market is expected to reach US$ 17,810.81 million by 2027 from US$ 12,721.85 million in 2019; it is estimated to grow at a CAGR of 4.4% from 2020 to 2027.
Rising prevalence of gastrointestinal (GI) diseases, and increase in development of biologics are the key factors driving the growth of gastrointestinal drugs. However, side effects associated with the drugs is the major factor hindering the market growth in Europe.Gastrointestinal (GI) disorders are the medical conditions related to the digestive system that affect the colon, small and large intestine, and rectum. The disorders include constipation, irritable bowel, ulcerative colitis, and peptic ulcer diseases. These disorders are characterized by various symptoms such as pain, bloating, diarrhoea, nausea, and vomiting. These disorders constitute a large proportion of outpatients and frequent hospital visits. A wide range of GI drugs is commercially available in the market for the treatment of various conditions. Additionally, rising investments in the development of biologics and the emergence of a biosimilar are expected to drive the growth of the market in the forecast period.
The European Medicines Agency approved the first biosimilar therapies in 2006. Europe has the largest number of approved biosimilar medicines owing to high biologic costs and demand for cheaper medicines. For example, several adalimumab biosimilars were launched in 2019 in Europe. Europe has witnessed a smooth transition toward the use of biosimilars owing to its well-established regulatory framework. However, due to lack of regulation, there are very few approved biosimilars in gastroenterology with more in the pipeline. In January 2016, 22 biosimilars have been approved by the European Medicines Agency. The first biosimilars for inflammatory bowel disease (IBD) in the European Union were registered in 2013, and the first use of biosimilars of infliximab (reference product Remicade, Janssen) began around the spring and summer of 2014. The approval of a biosimilar in GI disorders is expected to increase in the coming years.
For instance, In July 2020, Celltrion Healthcare received marketing authorization approval the European Commission (EC) for Remsima (infliximab, CT-P13). It is a subcutaneous formulation for the treatment of adult patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and psoriasis. Moreover, despite regulatory hurdles for the biosimilar market, it is still projected to grow at a rapid rate due to the need for cheaper alternatives to biologics. High costs associated with the manufacturing of biologic medicines have made biosimilar an attractive option for drug manufacturers, providing a platform for further growth.
The European economy is severely affected due to the exponential growth of COVID-19 cases in the region. Short-term impacts of COVID-19 pandemic includes demand changes, revision in regulatory process, changes in research and development process and the shift towards tele-communication and tele-medicine. But the growing awareness about gastrointestinal products available in market in Europe during is likely to demand for constipation drug products and supply in COVID-19 Pandemic, hence it can boost the growth of the gastrointestinal drugs market
Rest of Europe Gastrointestinal drugs Market, Revenue and Forecast to 2027 (US$ Mn)
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
EUROPE GASTROINTESTINAL DRUGS MARKET SEGMENTATION
By Drug Class
- Acid Neutralizers
- Antidiarrheal and Laxatives
- Anti-Inflammatory Drugs
- Antiemetic and Antinauseants
- Biologics
- Others
By Route of Administration
- Oral
- Parenteral
By Application
- Inflammatory Ulcerative Colitis
- Crohn's Disease
- Irritable Bowel Syndrome
- Gastroenteritis
- Celiac Disease
- Others
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Country
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Company Profiles
- Johnson and Johnson Services, Inc.
- Sanofi
- GlaxoSmithKline plc.
- AstraZeneca
- Bayer AG
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Drug Class, Route of Administration, Application, and Distribution Channel, and Country
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
UK, Germany, France, Italy, Russia
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Gastrointestinal Drugs Market – By Drug Class
1.3.2 Europe Gastrointestinal Drugs Market – By Route of Administration
1.3.3 Europe Gastrointestinal Drugs Market – By Application
1.3.4 Europe Gastrointestinal drugs Market – By Distribution Channel
1.3.5 Europe Gastrointestinal drugs Market – By Country
2. Europe Gastrointestinal Drugs Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Gastrointestinal Drugs Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Gastrointestinal Drugs Market - Europe PEST Analysis
4.3 Expert Opinion
5. Europe Gastrointestinal Drugs Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Rise in Prevalence of Gastrointestinal (GI) Diseases
5.1.2 Increase in Development of Biologics
5.2 Market Restraints
5.2.1 Side Effects Associated With The Drugs
5.3 Market Opportunities
5.3.1 Increasing Investment in Research Activities and Growing Pipeline of GI Candidates
5.4 Future Trends
5.4.1 Emergence of Biosimilars
5.5 Impact Analysis
6. Gastrointestinal Drugs Market – Europe Analysis
6.1 Europe Gastrointestinal Drugs Market Revenue Forecasts and Analysis
7. Europe Gastrointestinal Drugs Market Analysis And Forecasts To 2027 – By Drug Class
7.1 Overview
7.2 Europe Gastrointestinal Drugs Market, By Drug Class 2019 & 2027 (%)
7.2.1 Europe Gastrointestinal drugs Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
7.3 Acid Neutralizers
7.3.1 Overview
7.3.2 Europe Acid Neutralizers Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Antidiarrheal and Laxatives
7.4.1 Overview
7.4.2 Europe Antidiarrheal and Laxatives Market Revenue and Forecasts to 2027 (US$ Mn)
7.5 Anti-Inflammatory Drugs
7.5.1 Overview
7.5.2 Europe Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
7.6 Antiemetic and Antinauseants
7.6.1 Overview
7.6.2 Europe Antiemetic and Antinauseants Market Revenue and Forecast to 2027 (US$ Mn)
7.7 Biologics
7.7.1 Overview
7.7.2 Europe Biologics Market Revenue and Forecasts to 2027 (US$ Mn)
7.8 Others
7.8.1 Overview
7.8.2 Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)
8. Europe Gastrointestinal Drugs Market Analysis – By Route of Administration
8.1 Overview
8.2 Europe Gastrointestinal Drugs Market, By Route of Administration 2019-2027 (%)
8.2.1 Europe Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
8.3 Oral
8.3.1 Overview
8.3.2 Europe Oral Market Revenue and Forecasts to 2027 (US$ Mn)
8.4 Parenteral
8.4.1 Overview
8.4.2 Europe Parenteral Market Revenue and Forecasts to 2027 (US$ Mn)
9. Europe Gastrointestinal Drugs Market Analysis – By Application
9.1 Overview
9.2 Europe Gastrointestinal Drugs Market, By Application 2019-2027 (%)
9.2.1 Europe Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Application (US$ Mn)
9.3 Inflammatory Ulcerative Colitis
9.3.1 Overview
9.3.2 Europe Inflammatory Ulcerative Colitis Market Revenue and Forecasts to 2027 (US$ Mn)
9.4 Crohn's Disease
9.4.1 Overview
9.4.2 Europe Crohn's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Irritable Bowel Syndrome
9.5.1 Overview
9.5.2 Europe Irritable Bowel Syndrome Market Revenue and Forecasts to 2027 (US$ Mn)
9.6 Gastroenteritis
9.6.1 Overview
9.6.2 Europe Gastroenteritis Market Revenue and Forecasts to 2027 (US$ Mn)
9.7 Celiac Disease
9.7.1 Overview
9.7.2 Europe Celiac Disease Market Revenue and Forecasts to 2027 (US$ Mn)
9.8 Others
9.8.1 Overview
9.8.2 Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)
10. Europe Gastrointestinal Drugs Market Analysis – By Distribution Channel
10.1 Overview
10.2 Europe Gastrointestinal Drugs Market, By Distribution Channel 2019-2027 (%)
10.2.1 Europe Gastrointestinal Drugs Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
10.3 Hospital Pharmacies
10.3.1 Overview
10.3.2 Europe Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
10.4 Retail Pharmacies
10.4.1 Overview
10.4.2 Europe Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
10.5 Online Pharmacies
10.5.1 Overview
10.5.2 Europe Online Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
11. Gastrointestinal Drugs Market Revenue and Forecasts To 2027 – Geographical Analysis
11.1 Europe Gastrointestinal Drugs Market Revenue and Forecasts To 2027
11.1.1 Overview
11.1.2 Europe: Gastrointestinal Drugs Market - Revenue and Forecast to 2027 (USD Million)
11.1.3 Europe: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.4 Europe: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.5 Europe: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.6 Europe: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.7 Europe: Gastrointestinal Drugs Market, by Country, 2018 & 2027 (%)
11.1.8 Germany: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.1 Germany: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.8.2 Germany: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.8.3 Germany: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.8.4 Germany: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.8.5 Germany: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.9 UK: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.1 UK: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.9.2 UK: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.9.3 UK: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.9.4 UK: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.9.5 UK: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.10 France: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.1 France: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.10.2 France: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.10.3 France: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.10.4 France: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.10.5 France: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.11 Spain: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.11.1 Spain: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.11.2 Spain: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.11.3 Spain: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.11.4 Spain: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.11.5 Spain: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.12 Italy: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.12.1 Italy: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.12.2 Italy: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.12.3 Italy: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.12.4 Italy: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.12.5 Italy: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
11.1.13 Rest of Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.13.1 Rest of Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
11.1.13.2 Rest of Europe: Gastrointestinal Drugs Market, by Drug Class, 2018–2027 (USD Million)
11.1.13.3 Rest of Europe: Gastrointestinal Drugs Market, by Route of Administration 2018–2027 (USD Million)
11.1.13.4 Rest of Europe: Gastrointestinal Drugs Market, by Application 2018–2027 (USD Million)
11.1.13.5 Rest of Europe: Gastrointestinal Drugs Market, by Distribution Channel, 2018–2027 (USD Million)
12. Impact of COVID-19 Pandemic on Europe Gastrointestinal Drugs Market
12.1 Europe: Impact Assessment of COVID-19 Pandemic
13. Company Profiles
13.1 Sanofi
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 GlaxoSmithKline plc.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 AstraZeneca
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bayer AG
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Johnson and Johnson Services, Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
14. Appendix
14.1 Glossary of Terms
LIST OF TABLES
Table 1. Europe Gastrointestinal drugs Market Revenue and Forecasts To 2027, By Drug Class (US$ Mn)
Table 2. Europe Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
Table 3. Europe Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Application (US$ Mn)
Table 4. Europe Gastrointestinal Drugs Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
Table 5. Europe Gastrointestinal Drugs Market, by Drug Class– Revenue and Forecast to 2027 (USD Million)
Table 6. Europe Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 7. Europe Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 8. Europe Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 9. Germany Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 10. Germany Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 11. Germany Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 12. Germany Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 13. UK Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 14. UK Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 15. UK Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 16. UK Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 17. France Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 18. France Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 19. France Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 20. France Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 21. Spain Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 22. Spain Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 23. Spain Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 24. Spain Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 25. Italy Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 26. Italy Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 27. Italy Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 28. Italy Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 29. Rest of Europe Gastrointestinal Drugs Market, by Drug Class – Revenue and Forecast to 2027 (USD Million)
Table 30. Rest of Europe Gastrointestinal Drugs Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)
Table 31. Rest of Europe Gastrointestinal Drugs Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 32. Rest of Europe Gastrointestinal Drugs Market, by Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 33. Glossary of Terms, Gastrointestinal Drugs Market
LIST OF FIGURES
Figure 1. Gastrointestinal Drugs Market Segmentation
Figure 2. Europe Gastrointestinal Drugs Market Overview
Figure 3. Acid Neutralizers Segment Held Largest Share of Product in Gastrointestinal Drugs Market
Figure 4. UK is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. Europe Gastrointestinal Drugs Market - Leading Country Markets (US$ Mn)
Figure 6. Gastrointestinal Drugs Market - Europe PEST Analysis
Figure 7. Gastrointestinal Drugs Market Impact Analysis of Drivers and Restraint
Figure 8. Europe Gastrointestinal Drugs market – Revenue Forecasts and Analysis – 2019- 2027
Figure 9. Europe Gastrointestinal Drugs Market, By Drug Class 2019 & 2027 (%)
Figure 10. Europe Acid Neutralizers Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 11. Europe Antidiarrheal and Laxatives Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 12. Europe Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 13. Europe Antiemetic and Antinauseants Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 14. Europe Biologics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 15. Europe Anti-Inflammatory Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 16. Europe Gastrointestinal Drugs Market, by Route of Administration 2019 & 2027 (%)
Figure 17. Europe Oral Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 18. Europe Parenteral Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 19. Europe Gastrointestinal Drugs Market, by Application 2019 & 2027 (%)
Figure 20. Europe Inflammatory Ulcerative Colitis Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. Europe Crohn's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 22. Europe Irritable Bowel Syndrome Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 23. Europe Gastroenteritis Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 24. Europe Celiac Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 26. Europe Gastrointestinal Drugs Market, by Distribution Channel 2019 & 2027 (%)
Figure 27. Europe Hospital Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 28. Europe Retail Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 29. Europe Online Pharmacies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 30. Europe: Gastrointestinal Drugs Market, by Key Country – Revenue (2019) (USD Million)
Figure 31. Europe Gastrointestinal Drugs Market Revenue and Forecast to 2027 (USD Million)
Figure 32. Europe: Gastrointestinal Drugs Market, by Country, 2018 & 2027 (%)
Figure 33. Germany: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 34. UK: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 35. France: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 36. Spain: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 37. Italy: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 38. Rest of Europe: Gastrointestinal Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 39. Impact of COVID-19 Pandemic on Gastrointestinal Drugs market in European Countries
The List of Companies - Europe Gastrointestinal Drugs Market
- Sanofi
- GlaxoSmithKline plc
- Johnson and Johnson Services, Inc.
- AstraZeneca
- Bayer AG
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Europe Gastrointestinal Drugs Market
Nov 2020
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Nov 2020
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Nov 2020
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Nov 2020
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Nov 2020
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Nov 2020
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Nov 2020
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Nov 2020
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)